Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application

While mesenchymal stromal cells are an appealing therapeutic option for a range of clinical applications, their potential to induce clotting when used systemically remains a safety concern, particularly in hypercoagulable conditions, such as in patients with severe COVID‐19, trauma, or cancers. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Rourke, Brian, Nguyen, Sunny, Tilles, Arno W., Bynum, James A., Cap, Andrew P., Parekkadan, Biju, Barcia, Rita N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Enabling Technologies for Cell‐based Clinical Translation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133341/
https://www.ncbi.nlm.nih.gov/pubmed/33527780
http://dx.doi.org/10.1002/sctm.20-0454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133341/
https://www.ncbi.nlm.nih.gov/pubmed/33527780
http://dx.doi.org/10.1002/sctm.20-0454

Ejemplares similares